Literature DB >> 17699198

Highly active antiretroviral therapy and the kidney: an update on antiretroviral medications for nephrologists.

Jeffrey S Berns1, Nishaminy Kasbekar.   

Abstract

Highly active antiretroviral therapy has dramatically altered the treatment and life expectancy of individuals who are infected with HIV. More than 20 antiretroviral drugs and drug combinations now are available in the United States. Nephrologists need to have an understanding of the pharmacokinetics of antiretroviral medications and the proper dosing of these medications in patients with impaired kidney function. It is also important for nephrologists to be aware of drug-drug interactions that can occur between antiretroviral medications and other medications that they may prescribe, including immunosuppressive medications that are used for renal transplantation, as this becomes more common in HIV-infected patients. Adverse reactions that affect the kidneys and cause fluid-electrolyte complications occur with certain antiretroviral agents, although most are relatively free of nephrotoxicity. This article reviews the clinical pharmacology and dosing modifications of the newer antiretroviral medications in patients with reduced kidney function; important drug-drug interactions involving these medications, particularly with other medications that are likely to be prescribed by nephrologists; and renal toxicities of antiretroviral agents.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 17699198     DOI: 10.2215/CJN.00370705

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  17 in total

1.  HIV and HCV Medications in End-Stage Renal Disease.

Authors:  Keiko I Greenberg; Mark A Perazella; Mohamed G Atta
Journal:  Semin Dial       Date:  2015-04-06       Impact factor: 3.455

Review 2.  Novel Antiretroviral Drugs in Patients with Renal Impairment: Clinical and Pharmacokinetic Considerations.

Authors:  Dario Cattaneo; Cristina Gervasoni
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-08       Impact factor: 2.441

Review 3.  HIV-associated nephropathies: epidemiology, pathology, mechanisms and treatment.

Authors:  Avi Z Rosenberg; Saraladevi Naicker; Cheryl A Winkler; Jeffrey B Kopp
Journal:  Nat Rev Nephrol       Date:  2015-02-17       Impact factor: 28.314

Review 4.  Renal disease in patients with HIV infection: epidemiology, pathogenesis and management.

Authors:  Derek M Fine; Mark A Perazella; Gregory M Lucas; Mohamed G Atta
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 5.  HIV and kidney disease in sub-Saharan Africa.

Authors:  June Fabian; Saraladevi Naicker
Journal:  Nat Rev Nephrol       Date:  2009-10       Impact factor: 28.314

Review 6.  Renal effects of novel antiretroviral drugs.

Authors:  James Milburn; Rachael Jones; Jeremy B Levy
Journal:  Nephrol Dial Transplant       Date:  2017-03-01       Impact factor: 5.992

7.  Performance of creatinine and cystatin C GFR estimating equations in an HIV-positive population on antiretrovirals.

Authors:  Lesley A Inker; Christina Wyatt; Rebecca Creamer; James Hellinger; Matthew Hotta; Maia Leppo; Andrew S Levey; Aghogho Okparavero; Hiba Graham; Karen Savage; Christopher H Schmid; Hocine Tighiouart; Fran Wallach; Zipporah Krishnasami
Journal:  J Acquir Immune Defic Syndr       Date:  2012-11-01       Impact factor: 3.731

8.  HIV viremia and changes in kidney function.

Authors:  Chris T Longenecker; Rebecca Scherzer; Peter Bacchetti; Cora E Lewis; Carl Grunfeld; Michael G Shlipak
Journal:  AIDS       Date:  2009-06-01       Impact factor: 4.177

Review 9.  Carbon monoxide: An emerging therapy for acute kidney injury.

Authors:  Xiaoxiao Yang; Mark de Caestecker; Leo E Otterbein; Binghe Wang
Journal:  Med Res Rev       Date:  2019-12-09       Impact factor: 12.944

Review 10.  Genome-wide association studies on HIV susceptibility, pathogenesis and pharmacogenomics.

Authors:  Daniëlle van Manen; Angélique B van 't Wout; Hanneke Schuitemaker
Journal:  Retrovirology       Date:  2012-08-24       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.